FDA Seeks Approval for Emergency Drug Authorization Forms
Published Date: 11/24/2025
Notice
Summary
The FDA is asking for public feedback on their paperwork for emergency use authorizations (EUAs) of medical products, like vaccines or treatments used during health emergencies. This helps keep the process smooth and up-to-date without adding extra costs or delays. Comments are open until December 24, 2025, so anyone involved in medical product development or emergency response should take note!
Analyzed Economic Effects
6 provisions identified: 1 benefits, 5 costs, 0 mixed.
Recordkeeping Burden for EUA Holders
EUA holders must keep records under conditions of authorization; FDA estimates annual recordkeeping of 35,200 hours for EUA holders. The tables in the notice also report an overall recordkeeping total shown as 59,403 hours (including state and local entries), reflecting the paperwork time tied to maintaining required records.
EUA Application Reporting Burden
If you apply for an Emergency Use Authorization (EUA) or a substantive amendment, FDA estimates a total annual reporting burden of 6,435 hours across respondents for those requests. The estimate covers submissions to CBER, CDER, and CDRH and reflects the paperwork time required to request an EUA or amend an existing EUA.
Required Dissemination and Disclosure Burden
EUA holders and authorized stakeholders must disseminate required information (fact sheets, advertising, promotional materials); FDA estimates an annual third‑party disclosure burden of 6,920 hours for these activities. The estimate covers preparing and distributing required fact sheets and related informational materials.
Net Reduction in Paperwork Burden
FDA reports the estimated information collection burden reflects an overall decrease of 7,087 hours and a decrease of 302,456 responses compared to prior estimates. That reduction lowers the total paperwork burden for respondents covered by this collection.
Pre‑EUA Submission Time Burden
If you submit a pre‑EUA package (information for FDA review before an EUA), FDA estimates a total annual burden of 1,292 hours across respondents for pre‑EUA submissions and amendments. This covers preparedness-focused reviews by the Centers (CBER, CDER, CDRH) and reflects the paperwork time for voluntary pre‑submission engagement.
State/Local Public Health Authority Burdens
State and local public health authorities have specified submission and recordkeeping tasks tied to EUAs: the notice lists 2 hours for certain submissions required under conditions of authorization, 2 hours for requests for Emergency Dispensing Orders, 20 hours for expiration date extension requests to CDER, and 3 hours for recordkeeping in one table entry. These items reflect time public health authorities may need to spend on EUA-related actions.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-20770 — Submission for Office of Management and Budget Review; Trafficking Victim Assistance Program Data
The Office on Trafficking in Persons is asking to keep collecting info on how well the Trafficking Victim Assistance Program helps victims of human trafficking. This data helps improve services, report to Congress, and shape future support. If you want to share your thoughts, comments are due by December 24, 2025, with no new costs or big changes planned.
Next: 2025-20772 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; 510(k) Third-Party Review Program
The FDA is asking for public feedback on extending its 510(k) Third-Party Review Program, which lets private experts help review certain medical device applications. This program affects device makers who want faster reviews and keeps paperwork manageable. Comments are due by December 24, 2025, and the program helps speed up device approvals without extra costs to manufacturers.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in